|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is a mesangial proliferative glomerulonephritis which often shows proteinuria, an indicator for podocyte damage.
|
31600491 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is controversy over whether IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis (HSPN) are the same diseases.
|
31468231 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and has a broad range of histological and clinical manifestations, ranging from morphologically normal to globally sclerotic glomeruli with clinical manifestations varying from isolated hematuria to end stage renal disease.
|
31320251 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the leading primary GN worldwide.
|
31444275 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is a tonsil-related disease.
|
31088610 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide and a major cause of chronic kidney disease and failure.
|
31402200 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous genome-wide association studies have discovered significant association at ITGAX-ITGAM on 16p11.2 for IgA nephropathy (IgAN).
|
31227791 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide.
|
31542837 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant galactose-deficient IgA1 molecules (Gd-IgA1) are important causal factors in IgA nephropathy (IgAN); however, the detection of Gd-IgA1 in IgAN is complicated and instable.
|
31574506 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The onset of IgA nephropathy (IgAN), characterized by glomerular deposition of IgA-containing immune complexes, is often associated with synpharyngitic hematuria.
|
31489594 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of this study was to investigate whether NLRP3 expression associated with podocyte injury was involved in the pathogenesis of IgA nephropathy (IgAN).
|
31796125 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunoglobulin A (IgA) vasculitis nephritis (IgAV-N) is the most common secondary IgA nephropathy (IgAN).
|
31377786 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is one of the most common chronic glomerulonephritis.
|
31551340 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) was the most common subtype of primary glomerulonephritis (37.2%).
|
31198075 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It has been suggested that mesangial IgA deposits are dimeric or polymeric in IgA nephropathy (IgAN).
|
31354895 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In relation to control biopsies, podocyte-specific proteins were downregulated in podocytopathies, in proliferative nephritis, in diabetic kidney disease (DRD), and in IgA nephropathy (IgAN).
|
31220088 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide.
|
30832601 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hydroxychloroquine (HCQ), a well-known immunomodulator, has recently been found to be a promising and safe anti-proteinuric agent for treating IgA nephropathy (IgAN).
|
31382914 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is common and often progresses to end stage renal disease.
|
31351413 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Standard methods for detecting and monitoring of IgA nephropathy (IgAN) have conventionally required kidney biopsies or suffer from poor sensitivity and specificity.
|
31510053 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present work exploits modern methodology to estimate the total nephron number in glomerulopathies with prevalent proteinuria/nephrotic syndrome versus glomerulopathies with nephritic syndrome (IgA nephropathy (IgAN), lupus nephritis), thus extending previous observations about the number and function of glomeruli in different physiological and pathological states.
|
31534861 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunosuppressive agents have been widely used in the treatment of IgA nephropathy (IgAN), but the efficacy and safety remain controversial.
|
31455248 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical course of IgA nephropathy (IgAN) varies from asymptomatic nonprogressive to aggressive disease, with up to one in four patients manifesting ESRD within 20 years of diagnosis.
|
30971457 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Respiratory viral infections can directly lead to kidney damage such as IgA nephropathy (IgAN), partly due to mucosal immune system dysfunction.
|
31134161 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The addition of tubulointerstitial inflammation to the existing pathological classification of IgA nephropathy (IgAN) is appealing but was previously precluded due to reportedly wide inter-observer variability.
|
31198533 |
2019 |